2 0 1 6
A S H
The MMRF
makes a splash at ASH
Record-breaking 19 research presentations
from The MMRF CoMMpass StudySM data at ASH
T
he CoMMpass data is
becoming the data set
of choice for researchers
across the globe, validating
the importance of publically
available data, championed by
the MMRF. This collaborative
research effort is accelerating
actionable insights and the
pace of drug discovery and
development. The CoMMpass
Study data is already yielding
insights into new targets
and pathways for drug
development, as well as new
ways to identify and potentially
treat high-risk patients.
Which multiple myeloma
patients are at “high risk”
for early relapse?
Determining which patients relapse
quickly (less than 18 months) after
4
starting their first line
of therapy will allow
doctors to follow these
patients closely so that
they can receive the
appropriate treatment.
Three research groups
have identified sets of
genes and pathways
that are associated with
an increased chance of
early disease progression
David Siegel, MD, PhD
following treatment.
Chief, Division of Multiple Myeloma
Some of these gene
John Theurer Cancer Center
defects could be treated
with drugs currently
being used for other
cancers, while others
are new targets for
the next generation
this very question. These initiatives will
of anti-myeloma drugs. Because the
use the CoMMpass data to identify
identification of high-risk patients is so
common characteristics among patients
important, the MMRF highlighted at
who are high risk so that more tailored
ASH the initiation of two crowdsourcing
treatment strategies can be pursued.
initiatives, HBS/TopCoders and SAGE/
Dream, which will seek input from
researchers around the globe to answer
T H E M M R F.ORG